晚期卵巢癌盆腔整块切除术(EnBRP):10步标准化技术及初次与中间减瘤手术的手术与生存结局比较
该研究描述盆腔整块切除术(EnBRP)的10步标准化技术,并回顾性分析200例FIGO IIIC-IV期卵巢癌患者,其中92例(46%)行EnBRP,比较初次减瘤手术(48例)与中间减瘤手术(44例)的手术与生存结局。两组均实现完全切除,无术中特定并发症,肠吻合口裂开为唯一特定并发症(2%,每组各1例),总体并发症率33%(组1为35%,组2为31%),死亡率1%。中位无病生存期20个月,组1为25个月 vs 组2为15个月(P=0.009)。
要点
- EnBRP是一种安全有效的技术,可处理晚期卵巢癌的盆腔病变,出血少、切缘清晰率高、完全切除率高且手术并发症率低。
- 中位无病生存期组1(初次手术)25个月 vs 组2(中间手术)15个月(P=0.009)。
核心结论
- EnBRP是处理晚期卵巢癌患者盆腔病变的安全有效技术,出血少、切缘清晰率高、完全切除率高且手术并发症率低,尤其适合即将开始或重新开始化疗的患者。
研究设计与样本
- 回顾性分析200例FIGO IIIC-IV期卵巢癌接受内脏腹膜减灭术(VPD)且行EnBRP的患者,分为组1(初次VPD,48例)和组2(新辅助化疗后VPD,44例),比较两组手术与生存结局。
主要发现
- 200例中92例(46%)需要EnBRP,组1为48例,组2为44例。
- 所有患者均实现完全切除(CR),无术中特定并发症,肠吻合口裂开为唯一特定并发症,发生率2%(每组各1例),均通过肠道转流处理并好转。
- 总体并发症率33%,组1为35% vs 组2为31%;死亡率1%。
- 中位无病生存期20个月,组1为25个月 vs 组2为15个月(P=0.009)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In this study we describe the technique of the En-bloc resection of the pelvis (EnBRP) in 10 standardised and reproducible steps, whereby all pelvic organs, except the bladder, are removed together with the peritoneum. In addition, we compare the surgical and survival outcomes of patients who underwent upfront vs. interval surgery. METHODS: Retrospective analysis of patients with FIGO Stage IIIC-IV ovarian cancer treated with Visceral Peritoneal Debulking (VPD) who had EnBRP. The study population was divided into Group 1 (up-front VPD) and group 2 (VPD after neo-adjuvant chemotherapy). The aim was to assess the incidence of EnBRP. We also assessed rate of complete resection (CR), procedure-specific and overall morbidity, disease free and overall survival. Results were compared between group 1 and 2. RESULTS: Overall 92 out of 200 patients (46%) needed an EnBRP during the VPD. Forty-eight patients were in Group 1 and 44 patients in Group 2. CR was achieved in all patients. No intra-operative procedure specific morbidity was recorded. Dehiscence of bowel anastomosis was the only procedure specific morbidity. Rate was 2%, with 1 episode recorded in each group. Both patients were managed and settled with formation of a bowel diversion. The overall morbidity rate was 33%, 35% in group 1 and 31% in group 2. The mortality rate was 1%. Median disease free survival was 20months, 25 in group 1 vs. 15 in group 2 (P=0.009). CONCLUSIONS: EnBRP is a safe and effective technique to tackle the pelvic disease of patients with advanced ovarian cancer. The reduced blood loss, the high rate of clear margins and CR of the disease are accompanied by a low rate of surgical morbidity. These features are particularly suitable for patients who are due to start or re-start chemotherapy. The standardization of the technique will make it more reproducible and easier to be taught. In addition, it will facilitate comparison of results and the inclusion of this technique in the portfolio of procedures as part of debulking surgery.
引用
- Tozzi R, Hardern K, Gubbala K, et al. En-bloc resection of the pelvis (EnBRP) in patients with stage IIIC-IV ovarian cancer: A 10 steps standardised technique. Surgical and survival outcomes of primary vs. interval surgery. Gynecol Oncol. 2017. PMID: 28073597. doi:10.1016/j.ygyno.2016.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。